Caicun Zhou

List of Publications by Year
in descending order

17 papers	2,279 citations	687363 13 h-index	1058476 14 g-index
17 all docs	17 docs citations	17 times ranked	2805 citing authors

#	Article	IF	Citations
1	Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet, The, 2019, 394, 1929-1939.	13.7	1,274
2	cGAS-STING, an important pathway in cancer immunotherapy. Journal of Hematology and Oncology, 2020, 13, 81.	17.0	249
3	LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	1.1	192
4	Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 2983-2994.	12.0	115
5	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	1.1	108
6	MHC class II expression in lung cancer. Lung Cancer, 2017, 112, 75-80.	2.0	80
7	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	1.1	49
8	Alterations of DNA damage repair in cancer: from mechanisms to applications. Annals of Translational Medicine, 2020, 8, 1685-1685.	1.7	44
9	<p>Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer</p>. OncoTargets and Therapy, 2020, Volume 13, 6475-6483.	2.0	33
10	Galectin-9 in non-small cell lung cancer. Lung Cancer, 2019, 136, 80-85.	2.0	32
11	Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer. Translational Lung Cancer Research, 2019, 8, 748-759.	2.8	22
12	Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer. , 2020, 8, e001391.		20
13	<p>Third-Generation TKI Resistance Due to SCLC Transformation: A Case Report and Brief Review</p>. OncoTargets and Therapy, 2019, Volume 12, 11305-11311.	2.0	15
14	FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III. , 2021, 9, e002339.		15
15	Killer immunoglobulin-like receptors/human leukocyte antigen class-I, a crucial immune pathway in cancer. Annals of Translational Medicine, 2020, 8, 244-244.	1.7	14
16	Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer. , 2021, 9, e002554.		11
17	An immune-based risk-stratification system for predicting prognosis in pulmonary sarcomatoid carcinoma (PSC). OncoImmunology, 2021, 10, 1947665.	4.6	6